Table of Contents
Conference Papers in Medicine
Volume 2013, Article ID 293968, 3 pages
http://dx.doi.org/10.1155/2013/293968
Conference Paper

Oncothermia in HIV-Positive and -Negative Locally Advanced Cervical Cancer Patients in South Africa

1Radiation Sciences, University of the Witwatersrand Medical School, 7 York Road, Parktown, Johannesburg 2193, South Africa
2Radiation Biophysics, iThemba LABS, P.O. Box 722, Somerset West 7129, South Africa

Received 16 January 2013; Accepted 9 May 2013

Academic Editors: G. F. Baronzio, M. Jackson, and A. Szasz

This Conference Paper is based on a presentation given by Carrie A. Strauss at “Conference of the International Clinical Hyperthermia Society 2012” held from 12 October 2012 to 14 October 2012 in Budapest, Hungary.

Copyright © 2013 Carrie A. Strauss et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aim. Investigate the clinical, economic, and cellular effects of the addition of oncothermia to standard treatment for HIV-positive and -negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives. Evaluate the effect that the addition of oncothermia has on local disease control, progression-free survival, overall survival at 2 years, treatment toxicity, quality of life, economic impact, and HIV status of participants. Radiobiology investigations will evaluate thermoradiosensitivity and the molecular markers for thermoradiosensitivity. Methodology. Phase III randomised clinical trial involving 236 HIV-negative and -positive stage IIb-III locally advanced cervical cancer patients. Treatment includes cisplatin, external beam radiation, and brachytherapy. The study group will receive oncothermia treatments. Participants will be monitored for two years after completion of treatment. Hypothesis. The addition of oncothermia to standard treatment protocols will result in improved clinical response without increasing treatment toxicity in HIV-positive patients or raising healthcare costs.